MannKind | MNKD - Stock


MannKind reported $49.17M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
Adma Biologics USD 222.1M 15.63M Mar/2026
BioCryst Pharmaceuticals USD 5.98M 587K Mar/2026
Eli Lilly USD 14.53B 785M Mar/2026
Halozyme Therapeutics USD 155.47M 21.01M Mar/2026
Insmed USD 132.91M 841K Mar/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
MacroGenics USD 9.5M 1.59M Mar/2026
MannKind USD 49.17M 13.85M Mar/2026
Merck USD 6.48B 179M Mar/2026
Novavax USD 11.46M 87K Mar/2026
Novo Nordisk DKK 42.85B 2B Mar/2025
Pfizer USD 10.67B 13M Mar/2026
Sanofi EUR 22.69B 1.81B Dec/2025